NEW YORK - OS Therapies (OSTX), a biopharmaceutical company specializing in clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) treatments, has announced progress with regulatory ...
Der Hauptwirkstoff von OS Therapies, OST-HER2, hat in einer klinischen Phase-2b-Studie für Osteosarkom signifikante Vorteile gezeigt. Das Unternehmen entwickelt auch ADCs der nächsten Generation mit ...
NEW YORK - OS Therapies (OSTX), a biopharmaceutical company specializing in clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) treatments, has announced progress with regulatory agencies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback